These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30917901)

  • 1. Estimation of potency of Hepatitis B immunoglobulin marketed in India to evaluate the manufacturer's production consistency: Role of National Control Laboratory.
    Meena J; Sood S; Rani N; Bisht R; Kiran M; Chhabra R; Singh S; Chand S
    Biologicals; 2019 May; 59():72-73. PubMed ID: 30917901
    [No Abstract]   [Full Text] [Related]  

  • 2. Retesting and laboratory investigations.
    Davis JS
    J Pharm Sci Technol; 1994; 48(3):107-9. PubMed ID: 8069512
    [No Abstract]   [Full Text] [Related]  

  • 3. Bad medicine. Monitoring programs target substandard drugs.
    Grens K
    Mod Healthc; 2013 May; 43(20):30-1. PubMed ID: 23947275
    [No Abstract]   [Full Text] [Related]  

  • 4. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 5. The Food and Drug Administration Amendments Act and postmarketing commitments.
    Fain K; Daubresse M; Alexander GC
    JAMA; 2013 Jul; 310(2):202-4. PubMed ID: 23839755
    [No Abstract]   [Full Text] [Related]  

  • 6. Barriers and Opportunities for Use of Patient Registries in Medicines Regulation.
    Olmo CA; McGettigan P; Kurz X
    Clin Pharmacol Ther; 2019 Jul; 106(1):39-42. PubMed ID: 30970160
    [No Abstract]   [Full Text] [Related]  

  • 7. Can the Food and Drug Administration ensure that our pharmaceuticals are safely manufactured?
    Hubbard WK
    Arch Intern Med; 2009 Oct; 169(18):1655-6. PubMed ID: 19822821
    [No Abstract]   [Full Text] [Related]  

  • 8. Responsibility for pharmaceutical company samples.
    Reti S
    N Z Med J; 2005 May; 118(1215):U1472. PubMed ID: 15915193
    [No Abstract]   [Full Text] [Related]  

  • 9. [Importing medicines with quality assurance].
    Agência Nacional de Vigilância Sanitária - Anvisa
    Rev Saude Publica; 2004 Apr; 38(2):337-8. PubMed ID: 15122397
    [No Abstract]   [Full Text] [Related]  

  • 10. Rationale drug therapy: reasons for failure and suggestions for its implementation.
    Mathur GP; Kushwaha KP; Mathur S
    Indian Pediatr; 1993 Jun; 30(6):815-8. PubMed ID: 7726879
    [No Abstract]   [Full Text] [Related]  

  • 11. [Surveillance of drug use--pros and cons].
    Bruhn C
    Dtsch Med Wochenschr; 2009 Aug; 134(33):p29. PubMed ID: 19705346
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison between in vitro potency tests for Cuban hepatitis B vaccine: contribution to the standardization process.
    Cuervo ML; de Castro Yanes AF
    Biologicals; 2004 Dec; 32(4):171-6. PubMed ID: 15572098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What do stakeholders think about pharmacovigilance?
    Edwards IR; Graedon T
    Drug Saf; 2010 Aug; 33(8):619-21. PubMed ID: 20635819
    [No Abstract]   [Full Text] [Related]  

  • 14. CIHR appointment.
    Roos NP; Baird P
    CMAJ; 2010 Jan; 182(1):65. PubMed ID: 20064969
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug postmarketing studies.
    Kashoki M; Lee C; Jenkins J
    JAMA; 2013 Dec; 310(22):2459. PubMed ID: 24327044
    [No Abstract]   [Full Text] [Related]  

  • 16. Systems-based approach to risk management.
    Menighan TE
    J Am Pharm Assoc (2003); 2005; 45(2):116. PubMed ID: 15868747
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug postmarketing studies--reply.
    Fain K; Alexander GC
    JAMA; 2013 Dec; 310(22):2459-60. PubMed ID: 24327045
    [No Abstract]   [Full Text] [Related]  

  • 18. Health Canada's Progressive Licensing Framework.
    Yeates N; Lee DK; Maher M
    CMAJ; 2007 Jun; 176(13):1845-7. PubMed ID: 17576983
    [No Abstract]   [Full Text] [Related]  

  • 19. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

  • 20. [GVP (Good Vigilance Practice) regulation].
    Hattori Y
    Nihon Yakurigaku Zasshi; 2012 Sep; 140(3):127-30. PubMed ID: 22975827
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.